What is Cleome droserifolia used for in traditional medicine?

Cleome droserifolia has been used in Egyptian traditional medicine primarily for anti-diabetic applications, with desert communities employing the plant as part of folk remedies for metabolic conditions. Its status as an endangered medicinal plant suggests prolonged historical harvesting for therapeutic purposes, though specific preparation methods from classical texts are not well-documented in the current scientific literature.

Does Cleome droserifolia have proven anti-diabetic effects in humans?

No human clinical trials have evaluated Cleome droserifolia for anti-diabetic effects. Current evidence is limited to in vitro data showing that its ethanolic extract inhibits the carbohydrate-digesting enzyme alpha-amylase with an IC₅₀ of approximately 14.93 µg/mL, which is a biochemical marker relevant to postprandial glucose management, but this has not been tested in animals or humans.

What are the main active compounds in Cleome droserifolia?

The dominant bioactive compounds identified in Cleome droserifolia extracts include rutin at 15,900 µg/g, syringic acid at 5,320 µg/g, ellagic acid at up to 7,657 µg/g dry matter, chlorogenic acid at 987 µg/g, and vanillin at 1,425 µg/g. Secondary compounds include rosmarinic acid, kaempferol, quercetin, ferulic acid, and terpenoids such as buchariol and teucladiol, collectively contributing to the plant's antioxidant, anti-inflammatory, and cytotoxic activities.

Is Cleome droserifolia safe to take as a supplement?

The safety of Cleome droserifolia for human supplemental use has not been established; no human toxicology studies, dose-finding trials, or adverse effect reporting exists. A notable concern is that the dichloromethane fraction showed cytotoxic effects on normal human breast cells (MCF-10A) at an IC₅₀ of 57.34 µg/mL—lower than for cancer cells—indicating a lack of cellular selectivity that warrants caution before any human use is considered.

How does Cleome droserifolia compare to standard anti-inflammatory drugs?

In vitro, Cleome droserifolia ethanolic extract inhibits COX-1 and COX-2 enzymes at IC₅₀ values of 12.91 µg/mL and 21.63 µg/mL respectively, which are pharmacologically interesting concentrations in isolated enzyme assays. However, direct comparison to NSAIDs such as ibuprofen or celecoxib in human settings is not possible because no pharmacokinetic data exists showing whether orally consumed extract achieves these concentrations in human plasma or target tissues.

What is the most bioavailable form of Cleome droserifolia supplement?

Ethanolic extracts of Cleome droserifolia demonstrate the highest biological activity in research studies, with proven alpha-amylase inhibition (IC₅₀ ~14.93 µg/mL) and COX enzyme inhibition compared to other extraction methods. Standardized extracts are preferable to whole plant preparations since the active compounds are concentrated and more reliably dosed. Absorption may be enhanced when taken with meals containing fat, as some of the bioactive constituents appear to be fat-soluble.

Does Cleome droserifolia interact with diabetes or blood pressure medications?

Cleome droserifolia's alpha-amylase inhibitory activity may have additive effects when combined with prescription anti-diabetic medications like acarbose, potentially increasing the risk of hypoglycemia. Similarly, its COX inhibition mechanism could theoretically interact with NSAIDs or anticoagulants, though human interaction studies are limited. Individuals taking medications for diabetes, hypertension, or cardiovascular conditions should consult a healthcare provider before supplementing with Cleome droserifolia.

What clinical evidence supports the effectiveness of Cleome droserifolia compared to placebo?

Most evidence for Cleome droserifolia comes from in vitro studies demonstrating COX-1 (IC₅₀ 12.91 µg/mL) and alpha-amylase inhibition, with limited human clinical trials published to date. While traditional use in Middle Eastern and African medicine spans centuries, rigorous randomized controlled trials in humans are sparse, making it difficult to establish definitive efficacy claims. Researchers acknowledge the need for more human studies to translate the promising biochemical findings into measurable clinical outcomes for blood sugar control or inflammation reduction.

Cleome droserifolia

Cleome droserifolia contains high concentrations of rutin (15,900 µg/g), syringic acid (5,320 µg/g), and ellagic acid (2,830 µg/g), which collectively drive antioxidant, anti-inflammatory, and anti-diabetic bioactivities through radical scavenging and enzyme inhibition. In vitro studies show its ethanolic extract inhibits COX-1 and COX-2 at IC₅₀ values of 12.91 µg/mL and 21.63 µg/mL respectively, and suppresses amylase activity at an IC₅₀ of 14.93 µg/mL, indicating potential relevance to glycemic and inflammatory management.

Category: Middle Eastern Evidence: 1/10 Tier: Preliminary

Cleome droserifolia — Hermetica Encyclopedia

Origin & History

Cleome droserifolia is a wild herbaceous plant native to arid and semi-arid regions of North Africa and the Middle East, particularly Egypt, where it grows in desert and rocky terrains. It is considered an endangered medicinal plant, which has limited systematic cultivation and contributed to restricted access for research purposes. The plant has historically been harvested from wild populations in Egyptian desert ecosystems, where it survives harsh conditions that likely contribute to its dense accumulation of bioactive secondary metabolites.

Historical & Cultural Context

Cleome droserifolia holds a recognized place in Egyptian traditional medicine, where desert-dwelling communities have historically utilized wild-harvested plants for the management of metabolic and inflammatory conditions, including diabetes—a use pattern that has motivated contemporary phytochemical investigation. The plant's designation as an endangered medicinal species indicates sustained human harvesting pressure over generations, implying long-standing cultural valuation preceding modern scientific inquiry. In the broader context of North African ethnopharmacology, Cleome species have been employed across multiple regional traditions for wound healing, fever management, and gastrointestinal complaints, providing an ethnobotanical framework for the anti-inflammatory and anti-diabetic activities observed in laboratory studies. Specific classical or medieval pharmacopoeial references to Cleome droserifolia by name are not documented in the available literature, though its ecological range overlaps with plant-use zones described in historic Unani and traditional Arab medicine texts.

Health Benefits

- **Anti-Diabetic Potential**: The ethanolic extract inhibits alpha-amylase activity with an IC₅₀ of approximately 14.93±1.87 µg/mL, a mechanism relevant to reducing postprandial glucose spikes by slowing dietary carbohydrate breakdown.
- **Anti-Inflammatory Activity**: Cyclooxygenase inhibition by the ethanolic extract has been demonstrated in vitro, with COX-1 IC₅₀ of 12.91±0.5 µg/mL and COX-2 IC₅₀ of 21.63±0.8 µg/mL, suggesting a dual inhibitory profile comparable to some NSAIDs at the biochemical level.
- **Antioxidant Defense**: The methanolic extract exhibited 66.09%±1.92% DPPH and 81.14%±1.26% ABTS radical scavenging activity at 1,000 µg/mL, attributed primarily to polyphenols including rutin, ellagic acid, and chlorogenic acid.
- **Anticancer Activity (Preliminary)**: Dichloromethane fractions induced caspase-mediated apoptosis in MCF-7, MDA-MB-231, and HeLa cancer cell lines, with IC₅₀ values ranging from 73.23 to 122.8 µg/mL at 72 hours, though cytotoxicity to normal cells was also observed.
- **Phenolic-Rich Nutritional Profile**: With rutin concentrations reaching 15,900 µg/g of extract and ellagic acid at 2,830 µg/g, the plant offers a dense source of bioavailable flavonoids and phenolic acids linked to cardiometabolic and cellular protective functions.
- **Antimicrobial Potential**: The diverse terpenoid content—including monoterpenoids, diterpenoids, cembrenes, and sesquiterpenes such as buchariol and teucladiol—suggests antimicrobial utility consistent with other Cleome species, although direct antimicrobial assay data for this species remains limited.
- **Phytosterol and Glycoside Content**: The presence of daucosterol, cardenolides, and saponins implies potential membrane-stabilizing and cardioprotective activities, though these effects have not been formally quantified in isolated assays for this species.

How It Works

The anti-inflammatory mechanism of Cleome droserifolia operates primarily through inhibition of cyclooxygenase enzymes COX-1 and COX-2, reducing prostaglandin biosynthesis from arachidonic acid; the selectivity ratio suggests moderate COX-1 preference, which has implications for both efficacy and gastric tolerability. Anti-diabetic activity is mediated through competitive or non-competitive inhibition of alpha-amylase, the pancreatic enzyme responsible for hydrolyzing starch into absorbable sugars, thereby attenuating the glycemic index of carbohydrate-containing meals. Anticancer activity involves induction of the intrinsic apoptotic pathway, evidenced by caspase activation in breast and cervical cancer cell lines following exposure to the dichloromethane fraction, with the rich rutin and ellagic acid content likely contributing to DNA damage response and mitochondrial membrane disruption. Antioxidant activity is mediated through hydrogen atom transfer and electron donation by polyphenolic compounds—particularly rutin, chlorogenic acid, and ellagic acid—which quench reactive oxygen species before they can cause lipid peroxidation or nucleic acid damage.

Scientific Research

All published efficacy data for Cleome droserifolia derive exclusively from in vitro laboratory investigations; no human clinical trials, animal efficacy studies, or randomized controlled trials have been published as of the available literature. Cytotoxicity was evaluated in four human cell lines (MCF-7, MDA-MB-231, HeLa, MCF-10A) using standard MTT or equivalent viability assays, revealing IC₅₀ values between 57.34 and 122.8 µg/mL after 72-hour exposure. Enzyme inhibition studies employed standard spectrophotometric COX and amylase assays using isolated enzymes, producing reproducible IC₅₀ data but without cellular, pharmacokinetic, or in vivo validation. The evidence base is therefore classified as preliminary preclinical, and all reported bioactivities require confirmation in animal models and ultimately human trials before any clinical efficacy claims can be substantiated.

Clinical Summary

There are no published human clinical trials evaluating Cleome droserifolia for any indication. The totality of clinical-adjacent evidence consists of in vitro enzyme inhibition assays, cell viability studies in cancer and normal cell lines, and radical scavenging assays, none of which provide direct evidence of therapeutic effect in living organisms. While IC₅₀ values for COX inhibition (12.91–21.63 µg/mL) and amylase inhibition (14.93 µg/mL) are pharmacologically interesting, translation to human-relevant plasma concentrations after oral dosing has not been studied. Confidence in clinical benefit for any proposed indication—anti-diabetic, anti-inflammatory, or anticancer—must be rated as very low given the complete absence of human or animal in vivo efficacy and safety data.

Nutritional Profile

Cleome droserifolia is phytochemically dense rather than nutritionally significant as a macronutrient source. Dominant bioactive constituents include rutin at 15,900 µg/g extract (a flavonoid glycoside with established antioxidant and vascular protective properties), syringic acid at 5,320 µg/g (a methoxylated phenolic acid), ellagic acid at 1,460–7,657 µg/g dry matter (a polyphenol with antiproliferative properties), chlorogenic acid at 987 µg/g (a hydroxycinnamate with anti-diabetic relevance), vanillin at 1,425 µg/g, rosmarinic acid at 955 µg/g, kaempferol at 779 µg/g, quercetin at 432 µg/g, and ferulic acid at 264 µg/g. Additional phytochemical classes include terpenoids (monoterpenoids, diterpenoids, cembrenes, sesquiterpenes buchariol and teucladiol), cardenolides, saponins, tannins, catechins, and the phytosterol daucosterol. Macronutrient composition and micronutrient (vitamin and mineral) content have not been characterized in the available literature, and bioavailability of phenolic compounds in human gastrointestinal conditions has not been studied for this species.

Preparation & Dosage

- **Ethanolic Extract (Research Grade)**: Prepared from dried aerial shoots using ethanol as solvent; laboratory stock solutions used at 12.5–50 mg/mL, but no human dose has been established.
- **Methanolic Extract (Research Grade)**: Methanolic extraction yields high polyphenol concentrations including rutin at 15,900 µg/g; used in antioxidant and phytochemical profiling studies only.
- **Organic Solvent Fractions**: Dichloromethane, chloroform, ethyl acetate, n-hexane, and n-butanol fractions have been studied for differential bioactivity; the dichloromethane fraction shows the greatest cytotoxic activity but also the highest normal-cell toxicity.
- **Traditional Preparation (Ethnobotanical)**: While specific traditional preparation methods are not well-documented in the current literature, desert medicinal plants in the Egyptian tradition are typically prepared as aqueous decoctions or infusions of aerial parts.
- **No Standardized Commercial Form**: No commercially standardized supplement form, defined dosage range, or bioavailability-enhanced delivery system (e.g., liposomal or nanoparticle) has been established for human use.
- **Important Note**: No safe or effective human dose has been determined; supplemental use outside of supervised research settings is not supported by evidence.

Synergy & Pairings

No formal synergy studies have been conducted for Cleome droserifolia with other ingredients; however, based on its phenolic composition, theoretical synergies may exist with other alpha-amylase inhibitors such as white kidney bean extract (Phaseolus vulgaris) for enhanced postprandial glucose control through complementary enzyme inhibition mechanisms. The rutin and quercetin content may exhibit additive antioxidant activity when combined with vitamin C, as ascorbic acid can regenerate oxidized flavonoid radicals, extending their functional lifespan in biological systems. Given the COX inhibitory profile, combination with omega-3 fatty acids (which downregulate arachidonic acid availability) could theoretically produce complementary anti-inflammatory effects, though this remains entirely speculative in the absence of combinatorial studies.

Safety & Interactions

The most significant safety concern identified in published research is the cytotoxicity of the dichloromethane fraction toward normal MCF-10A breast epithelial cells (IC₅₀ of 57.34 µg/mL), which was actually lower than the IC₅₀ values observed in cancer cell lines, indicating a lack of selectivity that raises concern for systemic toxicity if bioactive fractions reach normal tissues at sufficient concentrations. No human adverse effect data, toxicology studies, lethal dose (LD₅₀) determinations, or organ-specific toxicity assessments have been published for any extract or fraction of Cleome droserifolia. Drug interactions have not been formally studied; however, given COX-1/COX-2 inhibitory activity, theoretical interactions with NSAIDs, anticoagulants (e.g., warfarin), and antiplatelet agents cannot be excluded, and the alpha-amylase inhibition profile suggests additive risk with antidiabetic medications. Use during pregnancy or lactation is not supported by any safety data, and given the absence of reproductive toxicology studies combined with the demonstrated cytotoxicity to normal cell lines, use in these populations should be avoided until comprehensive safety data are available.